Cambridge Cognition - £1.37 million of new eCOA contracts
The Company will provide the Client with a single vendor solution for all three studies, managing the procurement of licences, device provision, CANTABTM cognitive assessments, a centralised platform for data acquisition and storage, as well as trial management services. The Client and the Company will additionally collaborate on the design and testing of a new cognitive task for use in clinics. The contract also includes the provision of one-to-one training for study sites, as well as the licensing of eCOA instruments. These additional services, which amount to 44% of the contract value, will be provided by a subcontractor to
The three studies will include a total of 180 patients - 60 per clinical group - with the overall objective being to track early cognitive changes and motor signals associated with the drug being delivered. By delivering CANTABTM cognitive assessments and eCOA questionnaires and scales all one platform, the Client will be able to sensitively, efficiently and securely monitor three distinct clinical populations.
"We are pleased to welcome another pharmaceutical partner to our growing client base, using our innovative digital health technologies. This is the second partnership that has been secured on the strength of launching our enhanced eCOA solution in 2019; underlining the importance of continuing to invest in developing our digital solutions."
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
For further information, contact:
| || |
Tel: 012 2381 0700
finnCap Ltd (NOMAD and Joint Broker)
Tel: 020 7220 0500
| || |
Tel: 020 3903 7715
| || |
Tel: 020 3934 6630
Notes to Editors
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
Quick facts: Cambridge Cognition Holdings PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE